Inventor · disambiguated record
Luis Borges
Also filed as: BORGES LUIS · BORGES LUIS G · BORGES LUIS GHIRA · FANSLOW III WILLIAM C
17 granted patents·39 pending applications·261 citations·filing 1999–2024
92Inventor score
Files withCENTURY THERAPEUTICS INC15FIVE PRIME THERAPEUTICS INC13AMGEN INC12IMMUNEX CORP10BORGES LUIS G2
Top patents by PatentIndex Score
56 records- 0198US6413932B1Tek antagonists comprising soluble tek extracellular binding domainIMMUNEX CORP·Filed 2000·Granted Jul 2, 2002·176 cites·42 claims
- 0293US7067475B2Tek antagonistsIMMUNEX CORP·Filed 2003·Granted Jun 27, 2006·33 cites·17 claims
- 0391US11306144B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Apr 19, 2022·6 cites·45 claims
- 0490US11814431B2B7-H4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2020·Granted Nov 14, 2023·3 cites·48 claims
- 0583US6384203B1Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)IMMUNEX CORP·Filed 1999·Granted May 7, 2002·30 cites·18 claims
- 0682US11753475B2Bispecific-Fc moleculesAMGEN INC·Filed 2018·Granted Sep 12, 2023·1 cites·8 claims
- 0781US2024043542A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0881US2025206822A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0979US12195535B2Antibodies binding to VISTA at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2023·Granted Jan 14, 2025·0 cites·37 claims
- 1079US2023212297A1Bispecific fc moleculesAMGEN INC·Filed 2022·Application pending·0 cites
- 1178US7361330B2Methods of using flt3-ligand in the treatment of fibrosarcomaIMMUNEX CORP·Filed 2002·Granted Apr 22, 2008·5 cites·16 claims
- 1277US12173069B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Dec 24, 2024·1 cites·28 claims
- 1376US11634502B2Heterodimeric bispecific antibodiesAMGEN INC·Filed 2014·Granted Apr 25, 2023·2 cites·24 claims
- 1475US2025129166A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1573US2023055407A1V-c-fc-v-c antibodyAMGEN INC·Filed 2022·Application pending·0 cites
- 1672US2023013293A1B7-h4 antibodies and methods of use thereofFIVE PRIME THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1772US2023077648A1Heterodimeric Bispecific AntibodiesAMGEN INC·Filed 2022·Application pending·0 cites
- 1872US2024216429A1Chimeric antigen receptor system with adaptable receptor specificityCENTURY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1968US11883432B2Chimeric antigen receptor system with adaptable receptor specificityCENTURY THERAPEUTICS INC·Filed 2021·Granted Jan 30, 2024·0 cites·13 claims
- 2068US7150992B1Methods of preparing dendritic cells with flt3-ligand and antigenINNUNEX CORP·Filed 2000·Granted Dec 19, 2006·4 cites·5 claims
- 2168US2025059286A1Artificial cell death polypeptide for chimeric antigen receptor and uses thereofCENTURY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2268US2006292166A1Vaccine composition comprising Flt3-ligandIMMUNEX CORP·Filed 2006·Application pending·0 cites
- 2367US12269888B2Artificial cell death polypeptide for chimeric antigen receptor and uses thereofCENTURY THERAPEUTICS INC·Filed 2023·Granted Apr 8, 2025·0 cites·4 claims
- 2467US7875703B2LIR-9, a novel leukocyte immunoglobulin-like receptorIMMUNEX CORP·Filed 2007·Granted Jan 25, 2011·0 cites·6 claims
- 2567US2020071425A1Heterodimeric Bispecific AntibodiesAMGEN INC·Filed 2019·Application pending·0 cites
- 2663US11603406B2Antibodies binding to VISTA at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Mar 14, 2023·0 cites·39 claims
- 2763US2025360210A1Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereofCENTURY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2863US2016257748A1V-c-fc-v-c antibodyAMGEN INC·Filed 2014·Application pending·0 cites
- 2963US2020040075A1V-c-fc-v-c antibodyAMGEN INC·Filed 2019·Application pending·0 cites
- 3063US2025066728A1Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem CellsCENTURY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3162US2019002568A1Bispecific fc moleculesAMGEN INC·Filed 2018·Application pending·0 cites
- 3262US2016145340A1Bispecific-fc moleculesAMGEN INC·Filed 2014·Application pending·0 cites
- 3362US2014302037A1BISPECIFIC-Fc MOLECULESAMGEN INC·Filed 2014·Application pending·0 cites
- 3462US2025090582A1Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereofCENTURY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3561US2003165531A1Flt3-ligand as a vaccine adjuvantIMMUNEX CORP·Filed 2003·Application pending·0 cites
- 3660US2003027358A1Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)IMMUNEX CORP·Filed 2002·Application pending·0 cites
- 3760US2003060614A1Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR)IMMUNEX CORP·Filed 2002·Application pending·0 cites
- 3860US2014308285A1Heterodimeric bispecific antibodiesAMGEN INC·Filed 2014·Application pending·0 cites
- 3959US2025345425A1Cells engineered with an hla-e and hla-g transgeneCENTURY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4058US11661459B2Artificial cell death polypeptide for chimeric antigen receptor and uses thereofCENTURY THERAPEUTICS INC·Filed 2021·Granted May 30, 2023·0 cites·11 claims
- 4154US2022333073A1Compositions and Methods for Generating Gamma-Delta T Cells from Induced Pluripotent Stem CellsCENTURY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4253US2022332782A1Combined Artificial Cell Death/Reporter System Polypeptide for Chimeric Antigen Receptor Cell and Uses ThereofCENTURY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4353US2022331361A1Gene transfer vectors and methods of engineering cellsCENTURY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4452US12091462B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Sep 17, 2024·0 cites·20 claims
- 4552US2007025993A1Tek antagonistsIMMUNEX CORP·Filed 2006·Application pending·0 cites
- 4651US2022333074A1Compositions and Methods for Generating Alpha-Beta T Cells from Induced Pluripotent Stem CellsCENTURY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4747US2008102065A1Erythropoietin receptor extended duration limited agonistsBORGES LUIS G·Filed 2007·Application pending·0 cites
- 4846US2022184123A1Genetically Engineered Cells and Uses ThereofCENTURY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4946US2022348657A1Bioassay for t-cell co-stimulatory proteins containing fc domainsFIVE PRIME THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 5046US2008124340A1Erythropoietin receptor agonistsBORGES LUIS G·Filed 2007·Application pending·0 cites
Showing the top 50 of 56 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Luis Borges files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →